About

ANG Lifesciences India Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹53 Cr

P/E

—

P/B

1.0×

Dividend yield

0%

ROE

-19%

ROCE

-7%

Debt / equity

1.47

OPM

0.8%

EPS (TTM)

₹-8.5

Book value

₹40.5

52-week high

₹42.8

52-week low

₹18.4

₹40.2+19.7%1Y

Beta

0.15

Damps index moves

Volatility (1y)

55.7%

Annualised, daily returns

RSI (14)

78.6

Overbought territory

Rel. strength (1y)

5.1%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+High promoter holding of 70.6% with no pledge

Cons

−Low return on equity of -16.6% (3-yr avg)
−Thin operating margin of 0.8%
−Weak interest coverage of -0.6×

Research score

Structured signal from quality, growth, valuation and momentum.

40/100

Business quality: 5
Valuation: 50
Momentum: 63

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	146	93	93
COGS	95	60	61
Gross profit	51	33	32
	41	35	32
	10	-2	1
OPM %	6.6%	-2.4%	0.8%
Depreciation	8	7	6
Interest	11	9	8
	-1	2	1
Profit before tax	-11	-16	-13
Tax	-1	-3	-2
Tax %	-5.3%	-21%	-14.8%
PAT	-10	-12	-11
PAT margin %	-6.9%	-13.4%	-11.9%
EPS (₹)	-7.6	-9.4	-8.4
EPS adjusted (₹)	-7.8	-9.5	-8.5
Annual report	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2024	Mar 2025	Mar 2026
Equity capital	13	13	13
Reserves	63	51	40
	69	80	78
	97	85	79
Total equity & liabilities	242	230	209
	58	57	51
CWIP	0	—	—
Investments	0	0	0
	184	172	158
Total assets	242	230	209

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	-9	-0	11
	20	-2	1
	-10	2	-12
Net cash flow	0	-0	0
Free cash flow	-15	-4	11
CFO / Operating profit %	-98.3%	—	—

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 0%

Stock price CAGR

10 years: —
5 years: -29%
3 years: -19%
1 year: 14%

Return on equity

7 years: —
5 years: —
3 years: -18%
Last year: -21%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	34.9%	35.8%	34.8%
EBITDA margin %	6.6%	-2.4%	0.8%
EBIT margin %	0.9%	-9.7%	-6.1%
PAT margin %	-6.9%	-13.4%	-11.9%
Working capital
Receivable days	183	262	267
Inventory days	183	331	279
Payable days	254	404	317
NWC days	112	188	229
Leverage
Current ratio	1.2	1.12	0.97
Debt to EBITDA	7.18	—	110.76
Debt to equity	0.91	1.26	1.47
Interest coverage	0.2	-0.8	-0.6
Asset turnover	0.6	0.4	0.44
Return ratios
Return on assets %	-4.2%	-5.4%	-5.3%
Return on capital employed %	2%	-7.6%	-7%
Return on equity %	-13.3%	-19.4%	-20.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%	70.6%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%	29.4%
No. of shareholders	—	—	—	—	—	—	—	—	—	6,273	6,084	5,952

Promoter holding up 0 percentage points since Jun 2023.

7 deals · 2 Aug 2021 – 3 Jan 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
3 Jan 2024	CHAUHAN TRISHUL JITUSINH	Bulk	BSE	Sell	84,673	₹83.23	₹0.70 Cr
3 Jan 2024	CHAUHAN TRISHUL JITUSINH	Bulk	BSE	Buy	84,673	₹81.93	₹0.69 Cr
12 Nov 2021	ALPHA LEON ENTERPRISES LLP	Bulk	BSE	Buy	57,484	₹621.00	₹3.57 Cr
12 Nov 2021	ALPHA LEON ENTERPRISES LLP	Bulk	BSE	Sell	10,926	₹677.77	₹0.74 Cr
30 Sept 2021	WAYS VINIMAY PRIVATE LIMITED	Bulk	BSE	Sell	32,000	₹349.55	₹1.12 Cr
5 Aug 2021	WAYS VINIMAY PRIVATE LIMITED	Bulk	BSE	Sell	30,400	₹370.05	₹1.12 Cr
2 Aug 2021	WAYS VINIMAY PRIVATE LIMITED	Bulk	BSE	Sell	51,200	₹331.25	₹1.70 Cr

1–7 of 7

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Rajesh GuptaExecutive Director-MD
Mrs. Saruchi GuptaExecutive Director
Mr. Rohit MittalNon-Executive - Non Independent Director
Mr. Harvinder Singh DhamiNon-Executive - Independent Director
Mr. Sukhpal SinghNon-Executive - Independent Director
Mrs. ChetnaNon-Executive - Independent Director
Mrs. Saruchi GuptaChief Financial Officer
Ms. Harshita AggarwalCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in ANG Lifesciences India Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

10

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Interim dividend2 Nov 2021 · ex-date₹1

1

Board meeting to consider results14 Aug 2026

2

Bonus 1:413 Jul 2022 · ex-date
Bonus 1:122 Sept 2021 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

1 Oct 2026, 1:14 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

30 Sept 2026, 5:46 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Sept 2026, 5:40 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

7 Sept 2026, 10:56 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

7 Sept 2026, 8:49 pmAGM/EGM

Notice Of 20Th AGM Of The Company On Wednesday, 30Th September, 2026 At 12 :00 Noon. (IST) Through Video Conferencing (VC) / Other Audio Visual Means (OA VM).

AGM PDF

7 Sept 2026, 8:39 pmCorp. Action

Intimation Of Book Closure

Book Closure PDF

7 Sept 2026, 8:33 pmAGM/EGM

Intimation Of 20Th Annual General Meeting

AGM PDF

7 Sept 2026, 8:26 pmOthers

Board Meeting Outcome For Board Meeting Outcome For Intimation Of AGM

Outcome without intimation PDF

Date	Category	Subject	Filing
1 Oct 2026, 1:14 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 5:46 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management

Loading announcements…

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends1

Board meetings1

Bonus issues2

Announcements

Not in the F&O segment

Dividends1

Board meetings1

Bonus issues2

Ratio timeline

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

1

1

2

1

1

2